ISSN 1006-298X      CN 32-1425/R

导航

肾脏病与透析肾移植杂志 ›› 2014, Vol. 23 ›› Issue (2): 108-114.

• 论文 • 上一篇    下一篇

血栓性微血管病血清标志物诊断方法的建立与评估

  

  • 出版日期:2014-04-28 发布日期:2014-04-28

A biomarker panel for noninvasive diagnosis of thrombotic microangiopathy

  • Online:2014-04-28 Published:2014-04-28

摘要:

目的:血栓栓塞性微血管病(thrombotic microangiopathy, TMA)作为一种病理损害,往往预示着患者长期肾脏预后不良;找寻非活检的TMA诊断方法,对于临床评估肾脏损伤具有重要的意义。
方法:入选220例临床疑诊TMA的患者,根据肾活检结果,分为TMA组(n=51)和非TMA组(n=169)。比较两组的实验室检查指标的差异,依据Logistic回归,建立TMA诊断模型。进一步入选临床疑诊的独立TMA患者(n=46)以及临床疑诊TMA的SLE患者(n=157)中,验证和评估该模型诊断TMA的价值。
结果:TMA组和非TMA组随访12个月的肾存活率有明显差异性,TMA患者肾脏预后更差(P = 0.015)。TMA组的血小板(PLT)、血色素(Hb)、乳酸脱氢酶(LDH)、血清肌酐(Scr)、ADAMTS13活性和THBD,与非TMA组有显著(均P<0.05)。以这个6个指标纳入多因素logistic回归分析,结果表明,Scr,PLT,LDH和ADAMTS13活性为肾脏TMA病变的有效预测指标(均P<0.05)。据此,建立Logistic 回归方程:logitP=-0.371-0.002×ADAMTS13activity+0.140×SCr+0.004×LDH-0.010×PLT。Hosmer-Lemeshow检验的拟合良好(P=0.489)。在46例临床疑诊TMA的独立患者中验证,ROC曲线下面积(AUC)为0.815(P<0.001);在157临床疑诊TMA的SLE患者中,AUC为0.852(P<0.001),验证该模型具有较好的临床诊断TMA的价值。
结论:基于PLT、LDH、Scr和ADAMTS13活性发展了非活检的TMA诊断模型,对于临床疑诊患者有较高的诊断价值,具有较好的临床应用前景。

关键词: 血栓栓塞性微血管病, 非创伤性, 诊断

Abstract:

Abstract Objective: Thrombotic microangiopathy (TMA) is a pathologic lesion and predicts a worse prognosis in kidney. Microangiopathic hemolytic anemia and thrombocytopenia are often suggestive of this lesion, but the standard diagnostic test is still a renal biopsy. The objective of this study is to develop a noninvasive panel and validate its value of diagnosing TMA. Methodology: Two hundred twenty suspected patients were divided into TMA group (n=51) and non-TMA group (n=169) according to renal biopsy results. They were used to develop a diagnostic panel of TMA by binary logistic gression. The internal validation were then performed, including 46 independent patients and 157 patients with systemic lupus erythematosus (SLE) and the diagnostic value for TMA lesion was further evaluated. Results: The patients with TMA presented worse renal outcome after 12 months of follow-up (P=0.015), compared with those without TMA. A panel of 4 variables - levels of serum creatinine, platelets, LDH and ADAMTS13 activity discriminated between patients with TMA and those without (area under the curve [AUC], 0.800; 95% confidence interval [CI], 0.723 to 0.877; P<0.001): logitP= -0.371-0.002×ADAMTS13activity+0.140×SCr+0.004×LDH-0.010×PLT. This panel was internally validated in 46 independent patients (AUC, 0.815; P<0.001). The Hosmer-Lemeshow test indicated a good fit (P=0.489). In the set of suspected patients with SLE , the AUCs were 0.852 (P<0.001). Conclusions: A validated panel including serum creatinine, platelets, LDH and ADAMTS13 activity may be one of noninvasive utility in informing clinicians TMA diagnosis and and patients.

Key words: TMA,  noninvasive,  diagnosis